{"filing":{"accession_number":"0001493152-26-025270","cik":"0001535955","ticker":"LPCN","company_name":"Lipocine Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226025270/form8-k.htm"},"events":[{"id":9119,"run_id":8006,"accession_number":"0001493152-26-025270","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Lipocine disclosed presentation of Phase 3 clinical trial results for LPCN 1154 (oral brexanolone) for postpartum depression treatment at the ASCP Annual Meeting on May 26, 2026. While this represents material clinical progress for a biopharmaceutical company's lead candidate, it does not fit neatly into the standard taxonomy categories—it is neither an earnings release, M\u0026A activity, executive change, nor a negative event like impairment or litigation. The disclosure of positive Phase 3 data would materially affect investor assessment of the company's pipeline prospects and regulatory pathway.","company_name":"Lipocine Inc.","ticker":"LPCN","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":1622,"accession_number":"0001493152-26-025270","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Lipocine disclosed presentation of Phase 3 clinical trial results for LPCN 1154 (oral brexanolone) for postpartum depression treatment at the ASCP Annual Meeting on May 26, 2026. While this represents material clinical progress for a biopharmaceutical company's lead candidate, it does not fit neatly into the standard taxonomy categories—it is neither an earnings release, M\u0026A activity, executive change, nor a negative event like impairment or litigation. The disclosure of positive Phase 3 data would materially affect investor assessment of the company's pipeline prospects and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:33:48.002309+00:00","company_name":"Lipocine Inc.","ticker":"LPCN","filing_date":"2026-05-26"}]}